Recombinant Mouse IL-2 (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
IL-2_Mouse_Recombinant_Protein_BA_032913
HT-2 cell proliferation induced by mouse IL-2.
  • IL-2_Mouse_Recombinant_Protein_BA_032913
    HT-2 cell proliferation induced by mouse IL-2.
  • Recombinant_Mouse_IL-2_CF_012022
    Recombinant mouse IL-2 induces the proliferation of mouse HT-2 cell line in a dose dependent manner. BioLegend’s protein was compared side-by-side to a competitor’s equivalent product.
Cat # Size Price Quantity Check Availability
575402 10 µg $94.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575404 25 µg $211.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575406 100 µg $469.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
575408 500 µg $1465.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendocytes.

Technical data sheet

Product Details

Source
Mouse IL-2, amino acids Ala21-Gln169 (Accession # NM_008366) was expressed in E. coli.
Molecular Mass
The 150 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17,231 Da. The DTT-reduced protein and non-reduced protein migrates at approximately 18kDa by SDS-PAGE.
Purity
Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in 5 mM NaH2PO4, 5 mM citric acid, 350 mM NaCl, 1 mM TCEP, pH 4.0.
Endotoxin Level
Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
ED50 = 0.2 - 1.0 ng/ml, corresponding to a specific activity of 1.0 - 5.0 x106 units/mg, as determined by the dose dependent stimulation of CTLL2 cell proliferation.

The specific activity of recombinant mouse IL-2 is approximately 9.07 x 104 IU/µg when compared against the Non WHO Reference Material for Murine Interleukin-2 (NIBSC code: 93/566) as determined by the dose dependent stimulation of CTLL2 cell proliferation.

ED50 = 0.4 - 2.0 ng/ml, corresponding to a specific activity of 0.5 - 2.5 x106 units/mg, as determined by the dose dependent stimulation of HT-2 cell proliferation.

For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.
Application

Bioassay

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

(PubMed link indicates BioLegend citation)
  1. Detanico T, et al. 2011.J. Immunol. 187:82. PubMed
  2. Malu DT, et al. 2011. J. Immunol. 186:6271. PubMed
  3. Alcaide P, et al. 2012. J. Immunol. 188:1421. PubMed
  4. Williams JW, et al. 2013. Am J Physiol Lung Cell Mol Physiol. 305:693. PubMed
Product Citations
  1. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  2. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  3. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  4. Balood M, et al. 2022. Nature. 611:405. PubMed
  5. Benakis C, et al. 2022. Elife. 11: . PubMed
  6. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  7. Chan L, et al. 2022. Cells. 12: . PubMed
  8. Liu Z, et al. 2023. Breast Cancer Res. 25:10. PubMed
  9. Yang J, et al. 2021. Cancer Immunol Res. 9:200. PubMed
  10. Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed
  11. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  12. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  13. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  14. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  15. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  16. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  17. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  18. Adu-Berchie K, et al. 2023. Nat Commun. 14:3546. PubMed
  19. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  20. Ruscetti M, et al. 2020. Cell. 181:424. PubMed
  21. Liu B, et al. 2019. Nat Commun. 10:354. PubMed
  22. Zhou Z, et al. 2021. Nat Biomed Eng. 5:1320. PubMed
  23. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  24. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  25. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  26. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  27. Gomez–Lopez N, et al. 2019. J Immunol. 203:1793. PubMed
  28. Jacobsen JT, et al. 2021. Science. 373:. PubMed
  29. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  30. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  31. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  32. Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed
  33. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  34. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  35. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  36. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  37. Kania AK, et al. 2021. Immunohorizons. 5:918. PubMed
  38. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  39. Swan G, et al. 2021. Front Immunol. 12:641188. PubMed
  40. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  41. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
  42. Han S, et al. 2020. Oncoimmunology. 9:1737368. PubMed
  43. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  44. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  45. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  46. Pasciuto E, et al. 2020. Cell. 182:625. PubMed
  47. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  48. Loo CS, et al. 2020. Immunity. 53:143. PubMed
  49. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  50. Xu H, et al. 2021. J Clin Invest. 131:. PubMed
  51. Jiang P, et al. 2018. Nat Med. 24:1550. PubMed
  52. Roberts KJ, et al. 2021. Sci Rep. 11:19422. PubMed
  53. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  54. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  55. Mohammadpour H, et al. 2020. JCI Insight. 5:00. PubMed
  56. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  57. Detanico T, et al. 2011. J Immunol. 187:82. PubMed
  58. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  59. Bao K, et al. 2016. J Immunol. 197(11):4371-4381. PubMed
  60. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
  61. Frech M, et al. 2020. MethodsX. 7:101054. PubMed
  62. Choi HS, et al. 2020. Cell Rep. 30:2989. PubMed
  63. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed

Antigen Details

Structure
Cytokine
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Cell Biology, Stem Cells
Molecular Family
Cytokines/Chemokines
Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
UniProt
View information about IL-2 on UniProt.org
Go To Top Version: 5    Revision Date: 05/04/2020

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login/Register
Forgot your password? Reset Password
Request an Account